Atorvastatin and its metabolites are detectable in breast fine needle aspiration biopsies and its use is associated with decreased C-reactive protein (CRP). These results support atorvastatin further evaluation in phase II BC prevention studies. The gene discussed is CRP; the disease is breast cancer.